Wolfram Samlowski
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (20)
Year:
2026
Year:
2026
Year:
2026
Introduction: Historically, approximately 30–32% of uveal melanoma patients develop metastases and die within 5 years. Larger tumor dimensions and monosomy 3 and/or Class 2 gene expression profile of the tumor are associated with an increased risk of metastasis. We evaluated the performance of these prognostic markers in patients undergoing surveillance in a community medical oncology practice. Methods: Uveal melanoma patients treated by a single vitreoretinal surgical oncologist and monitored by a single medical oncologist were identified via a clinical database search for analysis. Specified prognostic markers were evaluated for sensitivity, specificity, positive and negative predictive value, as well as prognostic accuracy. Results: We identified 37 uveal melanoma patients, followed for a median of 4.0 ± 3.7 years. Twenty-seven (73%) patients underwent plaque brachytherapy with vitrectomy and silicone oil for radiation attenuation; seven (19%) patients underwent brachytherapy alone; three (8%) had enucleation. There were no intraocular treatment failures. Six (16.2%) patients developed metastasis, and only one patient died of metastatic disease. Disomy 3 and Class 1 accurately predicted a low risk for metastasis (>90% negative predictive value). However, monosomy 3 and Class 2 had a low positive predictive value and prognostic accuracy in “high-risk” patients. Conclusions: In this single-center cohort, we observed an unexpectedly low rate of 5-year metastasis. AJCC stage correlated poorly with metastasis or survival. Molecular prognostic results of Disomy 3 and Class 1 gene expression profile accurately predicted a “low” risk for metastasis (>90% negative predictive value). Further evaluation of these unique surgical techniques needs to be carried out.
Year:
2025
Year:
2025
Background: The immune checkpoint inhibitor cemiplimab has significant clinical activity in unresectable and metastatic cutaneous squamous cell carcinomas. There are limited real-world data available to assess the outcome of cemiplimab treatment in patients in a community practice setting. Methods: We conducted a retrospective analysis of treatment outcomes following cemiplimab treatment (350 mg IV every 3 weeks) of squamous cell skin cancer. An exploratory analysis was performed to evaluate patient subsets, including patients with locally advanced disease, regional or distant metastases, and “too numerous to count” primaries. Another small group of patients who did not respond to the initial four doses of cemiplimab were evaluated following added radiotherapy. Results: Of the 36 patients treated, 22 (61.1%) achieved complete remission, 10 (27.8%) experienced a partial response, 3 (8.3%) had stable disease, and 1 (2.8%) developed progressive disease. The median progression-free survival for the entire cohort was over 33 months. Overall, cemiplimab was well-tolerated, with no hospitalizations due to treatment-related toxicity. Conclusions: Cemiplimab produced complete remissions in over 60% of patients with locally advanced and metastatic squamous cell skin cancers, allowing elective treatment discontinuation. Addition of radiotherapy in cemiplimab-refractory patients appeared to increase tumor responsiveness. In contrast, patients with TNTC primary tumors frequently develop new primary skin cancers. Thus, improved treatment options for this patient subset are still needed.
Year:
2025
Background: Combination checkpoint inhibitor therapy with ipilimumab plus nivolumab has significantly improved the treatment of patients with metastatic melanoma. This regimen has induced durable complete remissions and improved survival. However, these benefits are associated with a high risk of immune-related side effects. We evaluated the usefulness of potential prognostic biomarkers as predictors of eventual treatment benefit. Methods: A retrospective chart review was conducted of all metastatic melanoma patients treated by a single oncologist with ipilimumab plus nivolumab for advanced cutaneous or subungual melanoma. Baseline biomarkers including BRAF mutation status, serum lactate dehydrogenase levels, PD-L1 expression, and tumor mutation burden were correlated with progression-free survival (PFS). Results: Treatment outcomes were analyzed in 54 sequential patients. BRAF mutation status did not correlate with PFS. Only rare patients presented with an elevated lactate dehydrogenase (LDH); thus, this marker did not prove informative. There was a strong correlation of increased PD-L1 expression with treatment response, and an independent correlation of tumor mutation burden with prolonged PFS. An exploratory analysis suggested that the combination of low tumor cell PD-L1 expression and a low tumor mutation burden predicted a very poor immunotherapy response. Conclusions: Tumor mutation burden and PD-L1 represent potential prognostic biomarkers for response to combination CKI therapy, while LDH and BRAF offer limited prognostic value. Further work will be needed to develop a predictive nomogram to better aid in predicting potential treatment benefit.
Year:
2025
Background: The immune checkpoint inhibitor cemiplimab has significant clinical activity in unresectable and metastatic cutaneous squamous cell carcinoma. There is limited real-world data available to assess the outcome of cemiplimab treatment in patients in a community practice setting. Methods: We conducted a retrospective analysis of treatment outcomes following cemiplimab treatment (350 mg iv every 3 weeks) of squamous cell skin cancer. An exploratory analysis was performed to evaluate patient subsets, including patients with locally advanced disease, regional or distant metastases, and "too numerous to count" primaries. Another small group of patients who did not respond to the initial 4 doses of cemiplimab were evaluated following added radiotherapy. Results: Of the 36 patients treated, 22 (61.1%) achieved complete remission, 10 (27.8%) experienced a partial response, 3 (8.3%) had stable disease, and 1 (2.8%) developed progressive disease. The median progression-free survival for the entire cohort was over 33 months. Overall, cemiplimab was well-tolerated, with no hospitalizations due to treatment-related toxicity. Discussion: Cemiplimab produced complete remissions in over 60% of patients with locally advanced and metastatic squamous cell skin cancers, allowing elective treatment discontinuation. Addition of radiotherapy in cemiplimab-refractory patients appeared to increase tumor responsiveness. In contrast, patients with TNTC primary tumors frequently developed new primary skin cancers. Thus, improved treatment options for this patient subset are still needed.
Year:
2025
Immune-mediated diarrhea represents a serious complication of checkpoint inhibitor therapy, especially following ipilimumab-based treatment. Efficient diagnosis and control of diarrhea remains an ongoing challenge. We developed an accelerated management paradigm for patients with ipilimumab-induced diarrhea. Patients who developed significant diarrhea (>five loose stools/day) were presumed to be developing immune colitis. Therapy was interrupted and patients were treated with a methylprednisolone dose pack. If diarrhea was not completely resolved, high-dose steroids and infliximab were promptly added. Only non-responding patients underwent further evaluation for infection or other causes of diarrhea. A total of 242 patients were treated with ipilimumab-based regimens. Forty-six developed significant diarrhea (19%) and thirty-four (74.4%) had a rapid resolution of diarrhea following glucocorticosteroid and infliximab treatment. The median time to resolution of diarrhea was only 8.5 ± 16.4 days. Accelerated treatment for presumed immune-mediated diarrhea resulted in the rapid control of symptoms in the majority of patients. There were no intestinal complications or deaths. Immunosuppressive therapy for diarrhea did not appear to decrease the remission rate or survival. After the control of diarrhea, most patients were able to continue their planned immunotherapy. Further testing in 11/46 patients with unresponsive diarrhea revealed additional diagnoses, allowing their treatment to be adjusted.
Year:
2024
Previous studies suggested that somatic BRAF and NRAS mutations in metastatic melanoma increase the risk for brain metastases. The risk related to other non-overlapping “driver” mutations is unknown. We performed a retrospective evaluation of the incidence, timing, and outcome of brain metastases in a population of melanoma patients that underwent uniform next-gen sequencing. All patients were treated with initial checkpoint inhibitor therapy. Seventeen of 88 patients (20.0%) developed brain metastases. Eleven patients had brain metastases at diagnosis (12.9%). These were all patients with BRAF V600 or NF1 mutations. Only six patients with NRAS, NF1, KIT, or BRAF mutations (including fusions/internal rearrangements experienced delayed CNS progression following immunotherapy (7.1%)). No “quadruple negative” patient developed brain metastases. Patients with brain metastases at diagnosis had a better outcome than those with delayed intracranial progression. Current predictive markers, (LDH, tumor mutation burden, and PDL1) were poorly correlated with the development of brain metastases. Treatment with immunotherapy appears to reduce the incidence of brain metastases. Next-gen molecular sequencing of tumors in metastatic melanoma patients was useful in identifying genetic subpopulations with an increased or reduced risk of brain metastases. This may allow eventual personalization of screening strategies.
Year:
2024
Year:
2024
Year:
2024
Year:
2023
Year:
2023
Year:
2023
Year:
2023
Year:
2022
Year:
2022
Year:
2021
Year:
2021
Collaborators (5)
Sandip Patel
Associate Professor
Moores Cancer Center, UC San Diego Health
Elad Sharon
Associate Professor
Harvard University
Young Kwang Chae
Northwestern University Feinberg School of Medicine
Razelle Kurzrock
-
Megan Othus
Fred Hutchinson Cancer Research Center
Make your next move.
Prepare your application
Review drafts before you send them.